Analysts See Upside Potential in Mid-Cap ETFs Despite Risks

Analysts project significant upside for the iShares Morningstar Mid-Cap Value ETF (IMCV) with a target price of $83.15, indicating a 13.95% upside from its recent trading price of $72.97. Notable holdings like UTHR, IP, and EXPE exhibit even larger potential growth.

Date: 12-05-2025

AI Rating: 7

Stock Price Analysis for IMCV and Its Holdings

The report indicates a strong upside potential for the iShares Morningstar Mid-Cap Value ETF (IMCV), with analysts confidently setting the 12-month target price at $83.15. This implies a notable gain of 13.95% from its current trading price of $72.97. For professional investors, this upside suggests that IMCV could be undervalued, positioning it attractively for short to mid-term investments.

Focusing on the underlying holdings within IMCV, a deeper look into United Therapeutics Corp (UTHR), International Paper Co (IP), and Expedia Group Inc (EXPE) reveals even more encouraging figures. UTHR has a current share price of $301.42 with a target price of $388.75, indicating a remarkable upside of 28.97%. For IP, the current price is $44.27 versus a target of $56.24, reflecting a 27.05% potential growth. Similarly, EXPE, trading at $156.66, has a target price of $197.72, showcasing a potential increase of 26.21%.

While the target prices suggest positive expectations, investors should remain cautious. The optimism indicated by these targets can be a double-edged sword, potentially leading to downward revision if the companies fail to meet high expectations. The investor’s sentiment regarding these stocks should also be informed by overall market conditions, recent developments, and competitive dynamics in relevant industries. Therefore, performing further research into these firms and any relevant news that could influence their performance will be crucial for risk management.

Given these dynamics, a deeper examination into aspects like earnings performance, price consistency, and overall market health will be essential for investors looking to capitalize on the projected growth.

Stocks: IMCV UTHR IP EXPE